Mohacsy's Safe Portfolio Member Forum

[n4807g]

Short answer...no. But if you review the work being done in biotechnology, the understanding of the various mechanisms cancer cells utilize to survive you'd be encouraged by the increased knowledge and understanding. There are a large number of concepts in the lab and in clinical trials that will prove/or disprove a lot of the theories surrounding cancer cell survival. The challenge to overcome is isolating the cancer cells from the normal cells. The state of the art today is not sufficiently developed to insure only cancer cells are eradicated during therapy. I believe within the next 10 years researchers will have learned enough to bring very effective therapies to market.

As an aside, I also believe that a patient investor who studies the smaller discovery stage biotechs can make a fortune choosing a few companies that will eventually have the answers.